Trevi Therapeutics (NASDAQ:TRVI) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a $19.00 price objective on the stock.

Other research analysts also recently issued research reports about the stock. Leerink Partners increased their price objective on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. B. Riley Financial raised shares of Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, November 17th. HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Wednesday, January 21st. Finally, Stifel Nicolaus raised their price target on Trevi Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Trevi Therapeutics presently has a consensus rating of “Buy” and an average target price of $21.10.

Trevi Therapeutics Stock Down 12.0%

Shares of TRVI stock opened at $11.70 on Monday. The company has a 50 day moving average price of $11.24 and a 200-day moving average price of $10.76. Trevi Therapeutics has a 52 week low of $4.85 and a 52 week high of $14.39. The firm has a market capitalization of $1.50 billion, a PE ratio of -31.62 and a beta of 0.94.

Institutional Trading of Trevi Therapeutics

Several large investors have recently added to or reduced their stakes in TRVI. Caitong International Asset Management Co. Ltd purchased a new stake in Trevi Therapeutics during the fourth quarter valued at approximately $50,000. Seven Fleet Capital Management LP purchased a new position in shares of Trevi Therapeutics during the 4th quarter worth $89,000. Invesco Ltd. boosted its stake in shares of Trevi Therapeutics by 3.3% during the 4th quarter. Invesco Ltd. now owns 498,926 shares of the company’s stock worth $6,247,000 after acquiring an additional 15,856 shares during the last quarter. KVP Capital Advisors LP bought a new stake in shares of Trevi Therapeutics during the 4th quarter valued at $5,183,000. Finally, XTX Topco Ltd bought a new stake in shares of Trevi Therapeutics during the 4th quarter valued at $1,049,000. 95.76% of the stock is currently owned by institutional investors.

Key Trevi Therapeutics News

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Trevi completed an end‑of‑Phase 2 meeting with the FDA and said it has gained alignment on its development program for idiopathic pulmonary fibrosis (IPF)‑related chronic cough; the company will run two Phase 3 trials of nalbuphine ER — a meaningful de‑risking step and a clear clinical catalyst. Article Title
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and set a $21 price target (roughly +79.5% vs. the $11.70 reference), providing analyst support that can attract momentum buyers. Article Title
• Positive Sentiment: D. Boral Capital also reaffirmed a “buy” and set a $19 price target (about +62% upside from the $11.70 reference), adding further institutional endorsement. Article Title
• Neutral Sentiment: TRVI was highlighted by a Zacks piece as one of three stocks showing momentum that could lead to a breakout in March — a market‑attention note that can amplify moves but is not a company‑specific fundamental change. Article Title
• Neutral Sentiment: Trevi is expected to report quarterly earnings on Tuesday — an event that could add short‑term volatility depending on guidance or cash‑balance commentary. Article Title
• Negative Sentiment: The stock dipped after the company said it plans parallel trials in a lung disease program, prompting investor concerns around complexity and timelines; Stifel pushed back on the timeline worries, but the initial reaction was negative. Article Title

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.